Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | MAOA | P21397 | 3/20 | 0.42 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.40 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.40 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALPG | P10696 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1155121 | 0.88 | MAOB (0.47) | MRGPRX4MAOBVCAM1ALDH1A1HPGD | |
| SCHEMBL1155502 | 0.84 | MAPT (0.46) | MRGPRX4MAOBVCAM1ALDH1A1MAPT | |
| SCHEMBL1154524 | 0.81 | MRGPRX4 (0.50) | MRGPRX4VCAM1ALDH1A1HPGDMAPT | |
| SCHEMBL1155166 | 0.80 | KMT2A (0.50) | MAOBALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL1155130 | 0.80 | MAOB (0.47) | MAOBMAOAPTGESALDH1A1HPGD | |
| SCHEMBL1154768 | 0.80 | MAOB (0.50) | MAOBALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL1154908 | 0.79 | HPGD (0.49) | MRGPRX4DCPSALDH1A1HPGDMAPT | |
| SCHEMBL1155388 | 0.78 | DHFR (0.50) | MRGPRX4MAOBMAOADHFRDCPS | |
| SCHEMBL1155283 | 0.74 | ALDH1A1 (0.43) | MRGPRX4MAOBALDH1A1HPGDMAPT | |
| SCHEMBL1155185 | 0.74 | HSPB1 (0.53) | MRGPRX4DHFRDCPSALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3121176-A1 | 2,4-DIAMINOQUINAZOLINES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY | Families of Spinal Muscular Atrophy (US) | 2017-01-25 | — | — | EP | disclosed |
| EP-1765810-B1 | 2,4-DIAMINOQUINAZOLINES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2514748-B1 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20160152577-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2016-06-02 | — | — | US | disclosed |
| US-9067897-B2 | 2,4-Diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2015-06-30 | — | — | US | disclosed |
| EP-2514748-A1 | 2,4-diaminoquinazolines for spinal muscular atrophy | Families of Spinal Muscular Atrophy (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20110112118-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-05-12 | — | — | US | disclosed |
| US-7888366-B2 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-02-15 | — | — | US | disclosed |
| EP-1765810-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | Decode Chemistry, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123724-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | DECODE CHEMISTRY, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050288314-A1 | 2,4-diaminoquinazolines for spinal muscular atrophy | DECODE CHEMISTRY, INC. (US) | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112118-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | SMN1; SMN2, MUSK, MYO3B | MRGPRX4 1940/4885MAOB 493/4885MAOA 534/4885 |
| US-20160152577-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | SMN1; SMN2, MUSK, MYO3B | MRGPRX4 1940/4885MAOB 493/4885MAOA 534/4885 |
| US-20050288314-A1 | 2,4-diaminoquinazolines for spinal muscular atrophy | SMN1; SMN2, MUSK, MYO3B | MRGPRX4 1940/4885MAOB 493/4885MAOA 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.